Evidence map›Paper›PMID 29399407›Full record

ArticleOncoimmunology

Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice.

Kathleen M Kokolus, Ying Zhang, Jeffrey M Sivik, Carla Schmeck, Junjia Zhu, Elizabeth A Repasky, Joseph J Drabick, Todd D Schell

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 128 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
128citing papers in PubMed, 4 pooled it
8.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

128 citing papers in PubMed, 4 syntheses or guidelines pooled it, 171 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

68 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Kathleen M KokolusDepartment of Microbiology and Immunology, Penn State College of Medicine, Hershey, PA, USA.
Ying ZhangDepartment of Public Health Sciences, Penn State College of Medicine, Hershey, PA, USA.
Jeffrey M SivikPenn State Health Milton S. Hershey Medical Center, Hershey, PA, USA.
Carla SchmeckDivision of Hematology and Oncology, Department of Medicine, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA.
Junjia ZhuDepartment of Public Health Sciences, Penn State College of Medicine, Hershey, PA, USA.
Elizabeth A RepaskyDepartment of Immunology, Roswell Park Cancer Institute, Buffalo, NY, USA.
Joseph J DrabickDivision of Hematology and Oncology, Department of Medicine, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA.
Todd D SchellDepartment of Microbiology and Immunology, Penn State College of Medicine, Hershey, PA, USA.
Penn State Milton S. Hershey Medical Center · USPennsylvania State University · USRoswell Park Comprehensive Cancer Center · US

Funding

VIRUSES AND CANCERT32CA060395 · NCI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI MEYERS, CRAIG M · 1994 to 2021
$4.3M
NCI NIH HHS T32 CA060395
6 · The paper itself

Abstract

Immunotherapy has expanded treatment options for cancers with historically poor outcomes, yet a significant proportion of patients still fail to achieve durable clinical benefit. We defined the contribution of β-adrenergic receptor (βAR) signaling, a component of the stress response, on success of immunotherapy for melanoma since the use of antagonists (β-blockers) is associated with improved clinical outcomes in some cancers. We show that metastatic melanoma patients who received immunotherapy had improved overall survival if they also received pan β-blockers. This retrospective analysis is reinforced by results showing that βAR blockade enhances the control of murine melanoma growth by anti-(α)PD-1 checkpoint blockade. However, this effect was most significant when β-blocker was combined with dual αPD-1 + high dose interleukin-2 therapy and was reproduced by selective blockade of β

Indexed as

Beta-adrenergic receptorBeta-blockersImmunotherapyMetastatic melanoma patientsMice

Identifiers

PMID29399407
PMCPMC5790362
OpenAlexW2768592202

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.